Beryllium and compounds CASRN 7440-41-7 | DTXSID4023913 | IRIS | US EPA, ORD
Gastrointestinal 2 x 10-3 Small intestinal lesions BMD10 : 4.6 x 10-1
Immune, Respiratory 2 x 10-5 Beryllium sensitization and progression to CBD LOAEL (HEC): 2.0 x 10-4
Carcinogenic potential cannot be determined (Oral route) Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996)
Known/likely human carcinogen (Inhalation route) Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996)
B1; probable human carcinogen. Based on the limited evidence of carcinogenicity in humans exposed to airborne beryllium (lung cancer) and sufficient evidence of carcinogenicity in animals (lung cancer in rats and monkeys inhaling beryllium, lung tumors in rats exposed to beryllium via intratracheal instillation, and osteosarcomas in rabbits and possibly mice receiving intravenous or intramedullary injection), beryllium is reclassified from a B2 (inadequate human data) to a B1 probable human carcinogen (limited human data) using criteria of the 1986 Guidelines for Carcinogen Risk Assessment. Using the 1996 proposed Guidelines for Carcinogen Risk Assessment, inhaled beryllium would be characterized as a "likely" carcinogen in humans, and the human carcinogenic potential of ingested beryllium cannot be determined.
Extrapolation Method: Relative risk
Tumor type(s): Lung cancer (Wagoner et al., 1980)
EPA Chemicals Dashboard - Beryllium and compounds